Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma

Oncotarget

Volumn 6, Issue 29, 2015, Pages 27332-27342

  Leshchenko, Violetta V ^a   Kuo, Pei Yu ^a   Jiang, Zewei ^a   Weniger, Marc A ^b   Overbey, Jessica ^a   Dunleavy, Kieron ^c   Wilson, Wyndham H ^c   Wiestner, Adrian ^b   Parekh, Samir ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; Mantle cell lymphoma; Methylation; Noxa; Resistance

Indexed keywords

BORTEZOMIB; CD19 ANTIGEN; DECITABINE; PROTEIN NOXA; ANTINEOPLASTIC AGENT; AZACITIDINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; PMAIP1 PROTEIN, HUMAN; PROTEASOME INHIBITOR; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CELL SELECTION; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DRUG POTENTIATION; EPIGENETICS; FEMALE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PROTEIN FUNCTION; TREATMENT RESPONSE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL SURVIVAL; CHEMISTRY; DNA MICROARRAY; DRUG RESISTANCE; GENETIC EPIGENESIS; LYMPHOMA, MANTLE-CELL; METABOLISM; NUDE MOUSE; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZACITIDINE; BORTEZOMIB; CELL LINE, TUMOR; CELL SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROTEASOME INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE;

EID: 84944452952     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2903     Document Type: Article

References (22)

1. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin PL, Choi E, Dumetrescu O, Esseltine D, Trehu E, et al. Phase II Clinical Experience with the Novel Proteasome Inhibitor Bortezomib in Patients with Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma. J Clin Oncol. 2005; 23:676-684.
2. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, et al. Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. J Clin Oncol. 2005; 23:667-675.
3. Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, et al. Genomewide DNA Methylation Analysis Reveals Novel Targets for Drug Development in Mantle Cell Lymphoma. Blood. 2010; 116:1025-1034.
4. Ploner C, Kofler R, Villunger A. Noxa: At the Tip of the Balance between Life and Death. Oncogene. 2008; 27:S84-S92.
5. Khulan B, Thompson RF, Ye K, Fazzari MJ, Suzuki M, Stasiek E, Figueroa ME, Glass JL, Chen Q, Montagna C, Hatchwell E, Selzer RR, Richmond TA, et al. Comparative Isoschizomer Profiling of Cytosine Methylation: The HELP Assay. Genome Res. 2006; 16:1046-1055.
6. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, et al. Bortezomib Induces DNA Hypomethylation and Silenced Gene Transcription by Interfering with Sp1/NF-?B-Dependent DNA Methyltransferase Activity in Acute Myeloid Leukemia. Blood. 2008; 111:2364-2373.
7. Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, Morishima Y, Nakamura S, Seto M. Genome-Wide Array-Based CGH for Mantle Cell Lymphoma: Identification of Homozygous Deletions of the Proapoptotic Gene Bim. Oncogene. 2004; 24:1348-1358.
8. Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A. Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma. Clin Cancer Res. 2011; 17:5101-5112.
9. Rizzatti EG, Mora-Jensen H, Weniger MA, Gibellini F, Lee E, Daibata M, Lai R, Wiestner A. Noxa Mediates Bortezomib Induced Apoptosis in Both Sensitive and Intrinsically Resistant Mantle Cell Lymphoma Cells and This Effect Is Independent of Constitutive Activity of the AKT and NF-KappaB Pathways. Leukemia Lymphoma. 2008; 49:798-808.
10. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C, MacBeth KJ. A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines. PLoS ONE. 2010; 5:e9001.
11. Chou TC, Talalay P. Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors. Adv Enzyme Reg. 1984; 22:27-55.
12. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T, Ron D, Chen W, Trenkle W, Wiestner A, Ye Y. ERAD Inhibitors Integrate ER Stress with an Epigenetic Mechanism to Activate BH3-Only Protein Noxa in Cancer Cells. Proc Natl Acad Sci USA. 2009; 106:2200-2205.
13. Yamashita M, Kuwahara M, Suzuki A, Hirahara K, Shinnaksu R, Hosokawa H, Hasegawa A, Motohashi S, Iwama A, Nakayama T. Bmi1 Regulates Memory CD4 T Cell Survival Via Repression of the Noxa Gene. J Exp Med. 2008; 205:1109-1120.
14. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, Stampfer MR, Futscher MR. Role for DNA Methylation in the Regulation of MiR-200c and MiR-141 Expression in Normal and Cancer Cells. PLoS ONE. 2010; 5:e8697.
15. Lerner M, Haneklaus M, Harada M, Grandér D. MiR-200c Regulates Noxa Expression and Sensitivity to Proteasomal Inhibitors. PLoS ONE. 2012; 7:e36490.
16. Mei Y, Xie C, Xie W, Tian X, Li M, Wu M. Noxa/Mcl-1 Balance Regulates Susceptibility of Cells to Camptothecin-Induced Apoptosis. Neoplasia. 2007; 9:871-881.
17. Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu C, Raghavachari N, Stetler-Stevenson M, Yuan C, et al. Bortezomib Resistance in Mantle Cell Lymphoma Is Associated with Plasmacytic Differentiation. Blood. 2011; 117:542-552.
18. Schewe DM, Aguirre-Ghiso JA. Inhibition of eIF2alpha Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome Inhibitor Therapy. Cancer Res. 2009; 69:1545-1552.
19. Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, Bradley S, Gobburu JV, Goheer A, Lee SL, Leighton J, Liang CY, Lostritto RT, et al. Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma. Clin Cancer Res. 2004; 10:3954-3964.
20. Shaknovich R, Figueroa ME, Melnick A. HELP Assay for DNA Methylation Profiling of Primary Normal and Malignant B Lymphocytes. Methods Mol Biol. 2010; 632:191-201.
21. Thompson RF, Suzuki M, Lau KW, Greally JM. A Pipeline for the Quantitative Analysis of CG Dinucleotide Methylation Using Mass Spectrometry. Bioinformatics. 2009; 25:2164-2170.
22. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK, van den Boom D. Quantitative High-Throughput Analysis of DNA Methylation Patterns by Base-Specific Cleavage and Mass Spectrometry. Proc Natl Acad Sci USA. 2005; 102:15785-15790.